Scienture rises after deals to expand reach of opioid overdose spray

Scienture Holdings

11/03/2026 12:41

** Shares of specialty pharma firm Scienture Holdings SCNX.O rise 62% to $0.64 premarket

** Co says it has signed multiple GPO deals to distribute its high‑dose naloxone spray Rezenopy across 5,000+ U.S. healthcare sites

**  Adds agreements provide access to hospitals, clinics, nursing homes and EMS providers representing ~60% of U.S. institutional market

**  Naloxone reverses opioid overdoses and Rezenopy is the highest‑dose nasal spray approved in the U.S. - SCNX

**  Co says Rezenopy was approved in April 2024 and is supplied as a carton with two single‑use spray devices

**  Acquired exclusive U.S. rights to the product from Summit Biosciences in March 2025 - SCNX

** SCNX rose ~28% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))